Dexcom IncDXCM
What Dexcom Inc does.
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world.
We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025. In August 2024, we launched Stelo, our biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S.
Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.9B | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| Net income | $549.7M | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M |
| Free cash flow | $276.6M | $53.3M | $304.7M | $511.9M | $630.7M | $1.1B |
More on DXCM.
- Dexcom Inc summary
- Dexcom Inc financial statements
- Dexcom Inc key metrics
- Dexcom Inc health scores and style box
- Dexcom Inc earnings
- Dexcom Inc dividends
- Dexcom Inc valuation
- Dexcom Inc ownership and insiders
- Dexcom Inc peers
Figures from Dexcom Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.